Nerva Completes Mahana Therapeutics Acquisition to Expand Access to Digital Therapies for IBS (BioSpace)

On May 6, 2025, Nerva, a leading digital therapeutic for IBS, announced the acquisition of key assets from Mahana Therapeutics, a pioneer in digital therapies for chronic conditions. This move solidifies Nerva’s leadership in app-based brain-gut therapies, aiming to improve access to evidence-based care like gut-directed hypnotherapy and CBT for IBS. Nerva will integrate Mahana’s proven CBT programs into its own platform, expanding reach and effectiveness. The acquisition follows growing support from organizations like AGA and ACG for digital therapeutics in IBS care.